| アブストラクト | BACKGROUND: The potential risks of denosumab on pediatric patients have raised concerns about its safety. This article aims to analyze the adverse effects of denosumab in minors, with a specific focus on hypercalcemia. RESEARCH DESIGN AND METHODS: A case study involving a child was analyzed. The OpenVigil 2.1 was utilized to extract adverse event data from the FAERS database, focusing on denosumab as the primary suspect drug in pediatric patients. The study also reviewed published cases of children developing hypercalcemia after discontinuing denosumab. RESULTS: The incidence of denosumab induced hypercalcemia in individuals under 18 years old is significantly higher than the overall incidence. The signal value for hypercalcemia was higher in the male group and was highest in the adolescent group. Hypercalcemia usually appeared approximately 4 months after denosumab discontinuation. Males had a higher peak blood calcium level. Patients aged 0-11 years had a higher average peak serum calcium compared to aged 12-17 years. CONCLUSIONS: This study highlights the risk of hypercalcemia after discontinuation of denosumab in minors, with young age and male gender identified as potential high-risk factors. These findings offer valuable safety warnings and preventative measures for the secure administration of this drug in pediatric populations. |
|---|
| ジャーナル名 | Expert opinion on drug safety |
|---|
| Pubmed追加日 | 2024/7/15 |
|---|
| 投稿者 | Chen, Yiyu; Fang, Chuxuan; Yang, Zhiyong; Qiu, Guosheng; Tang, Shuangyi |
|---|
| 組織名 | Department of Pharmacy, The First Affiliated Hospital of Guangxi Medical;University, Nanning, China.;Department of PICU, The First Affiliated Hospital of Guangxi Medical University,;Nanning, China. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/39007894/ |
|---|
